pergolide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dopamine receptor agonists, ergoline derivatives 2105 66104-22-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • LY-127,809
  • LY127,809
  • permax
  • LY 127809
  • pergolide mesilate
  • pergolide mesylate
  • pergolide
A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.
  • Molecular weight: 314.49
  • Formula: C19H26N2S
  • CLOGP: 4.40
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 19.03
  • ALOGS: -5.73
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.14 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 38 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.441 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.555 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 33.343 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 39.719 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 7.110 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 15.610 % High 1
herg hERG pIC50 5.554 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 29.648 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 183.654 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 5.660 % High 1
kinase-safety-class ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK,ZAP70 46
kinase-selectivity-class AXL,BRAF,EIF2AK3 3
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.716 High 1
mh-clint Mouse hepatocyte intrinsic clearance 280.543 High 1
mppb Mouse plasma protein binding (% unbound) 9.480 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.782 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 24.490 % High 1
rh-clint Rat hepatocyte intrinsic clearance 294.442 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 37.870 % High 1
rppb Rat plasma protein binding (% unbound) 6.170 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 211.349 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gambling disorder 105.96 79.63 16 180 1760 42619379

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gambling disorder 116.39 93.04 16 198 2175 110586910

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BC02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA CS M0007656 Ergot Alkaloids
FDA MoA N0000000117 Dopamine Agonists
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018491 Dopamine Agonists
FDA EPC N0000175767 Ergot-derived Dopamine Receptor Agonist
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:51065 dopamine agonist
CHEBI has role CHEBI:176497 geroprotector

Related Drugs by ATC class:

N04BC Dopamine agonists 8 drugs
apomorphinebromocriptinecabergolinedihydroergocryptinepiribedilpramipexoleropinirolerotigotine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinsonism indication 32798002
Heart valve disorder contraindication 368009 DOID:4079
Pericarditis contraindication 3238004 DOID:1787
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Retroperitoneal fibrosis contraindication 49120005
Kidney disease contraindication 90708001 DOID:557
Pleurisy contraindication 196075003
Renal fibrosis contraindication 197660000
Pericardial effusion contraindication 373945007 DOID:118
Breastfeeding (mother) contraindication 413712001
Fibrosis of pleura contraindication 442110002
Pleural Effusions contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Horses Control of clinical signs associated with pituitary pars intermedia dysfunction (Equine Cushings Disease) Indication

🐶 Veterinary products

ProductApplicantIngredients
Prascend Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.41 acidic
pKa2 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST EC50 8.30 WOMBAT-PK DRUG LABEL
D(1A) dopamine receptor GPCR AGONIST Ki 6.47 SCIENTIFIC LITERATURE DRUG LABEL
5-hydroxytryptamine receptor 1A GPCR Ki 8.50 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR EC50 8.10 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR EC50 8.20 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR EC50 6.50 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.75 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 5.98 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.50 WOMBAT-PK
D(3) dopamine receptor GPCR AGONIST EC50 9 WOMBAT-PK
D(1B) dopamine receptor GPCR AGONIST Ki 6.76 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR EC50 6.60 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 7.90 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.20 WOMBAT-PK
Cytochrome P450 2D6 Enzyme IC50 6.70 DRUG MATRIX
D(4) dopamine receptor GPCR AGONIST Ki 7.25 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.13 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 7.30 WOMBAT-PK
Alpha-synuclein Transporter IC50 5.10 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.16 PDSP
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 5.84 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 7.40 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 5.71 CHEMBL
D(2) dopamine receptor GPCR Kd 8.40 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 7.82 CHEMBL
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 9 IUPHAR
D(2) dopamine receptor GPCR IC50 7.32 CHEMBL
D(3) dopamine receptor GPCR IC50 8.62 CHEMBL
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 7.50 IUPHAR
Adrenergic receptor alpha-2 GPCR IC50 7.39 CHEMBL
Dopamine receptor GPCR IC50 7.74 CHEMBL
Dopamine receptor GPCR IC50 8.51 CHEMBL
Cerebral cortex alpha adrenergic receptor GPCR IC50 7.39 CHEMBL

External reference:

IDSource
D00502 KEGG_DRUG
66104-23-2 SECONDARY_CAS_RN
4019530 VANDF
4019883 VANDF
C0031007 UMLSCUI
CHEBI:63617 CHEBI
CHEMBL531 ChEMBL_ID
CHEMBL1275 ChEMBL_ID
DB01186 DRUGBANK_ID
D010479 MESH_DESCRIPTOR_UI
47811 PUBCHEM_CID
48 IUPHAR_LIGAND_ID
4651 INN_ID
24MJ822NZ9 UNII
203553 RXNORM
2257 MMSL
45580 MMSL
5259 MMSL
d00977 MMSL
003442 NDDF
003443 NDDF
108468004 SNOMEDCT_US
108469007 SNOMEDCT_US
372498008 SNOMEDCT_US
24MJ822NZ9 INXIGHT DRUGS

Pharmaceutical products:

None